MENU
Showcases Stock ranks Forex

Fortress Biotech Inc (FBIO)
3.68  0.07 (1.94%) 05-14 16:00
Open: 3.75 Pre. Close: 3.78
High: 3.86 Low: 3.66
Volume: 577,296 Market Cap: 358M
Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. The company is headquartered in New York City, New York and currently employs 88 full-time employees. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 3.866 - 3.887 3.887 - 3.907
Low: 3.604 - 3.632 3.632 - 3.657
Close: 3.64 - 3.68 3.68 - 3.716
Stock Technical Analysis
Overall:     
Target: Six months: 5.96
One year: 7.12
Support: Support1: 3.49
Support2: 2.90
Resistance: Resistance1: 5.10
Resistance2: 6.10
Pivot: 4.05
Moving Averages: MA(5): 3.71
MA(20): 4.07
MA(100): 3.88
MA(250): 3.39
MACD: MACD(12,26): -0.15
Signal(12,26,9): -0.07
%K %D: %K(14,3): 11.68
%D(3): 12.20
RSI: RSI(14): 39.81
52-Week: High: 5.08
Low: 1.81
Change(%): 40.5
Average Vol(K): 3-Month: 201459
10-Days: 96024
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.

FBIO has closed above bottom band by 19.4%. Bollinger Bands are 1.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Sun, 16 May 2021
Is Fortress Biotech (NASDAQ:FBIO) Weighed On By Its Debt Load? - Yahoo Finance Australia

Thu, 13 May 2021
Fortress Biotech, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Yahoo Finance

Thu, 13 May 2021
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates - Nasdaq

Mon, 10 May 2021
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and - GlobeNewswire

Tue, 04 May 2021
Is Fortress Biotech (FBIO) a Stock to Watch After Losing -5.99% This Week? - InvestorsObserver

Thu, 29 Apr 2021
Fortress Bio: Interesting Model Of Doing Medicine - Seeking Alpha

Financial Analysis
Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 94.91
Shares Float (M) 56.56
% Held by Insiders 31.39
% Held by Institutions 34.61
Shares Short (K) 1760
Shares Short Prior Month (K) 1450
Stock Financials
EPS -0.646
Book Value (p.s.) 1.060
Profit Margin -102.03
Operating Margin -206.74
Return on Assets (ttm) -21.2
Return on Equity (ttm) -76.4
Qtrly Rev. Growth 23.5
Gross Profit (p.s.) 0.327
Sales Per Share 0.480
EBITDA (p.s.) -0.954
Qtrly Earnings Growth
Operating Cash Flow (M) -83.68
Levered Free Cash Flow (M) -55.83
Stock Valuation
PE Ratio -5.70
PEG Ratio
Price to Book value 3.47
Price to Sales 7.66
Price to Cash Flow -4.17
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator